Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUX-ECP in Steroid-Refractory Chronic Graft-versus-Host Disease
2023-507754-33-00Phase 2Authorised
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib and methoxsalen in graft-versus-host disease (GVHD), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Overall Response Rate at week 25. Planned start Feb 2025; status: authorised.
02
Drugs
ruxolitinibmethoxsalen
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2023-507754-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507754-33-00.